Bruker Corp Stock Price, News & Analysis

Bruker Corporation (Nasdaq: BRKR) has completed a private placement of 10-year senior notes totaling $500 million to enhance financial flexibility and support growth initiatives. The issuance includes 300 million Swiss Franc 0.88% Series A senior notes and 150 million Euro 1.03% Series B senior notes, both due December 8, 2031. The funds will be used for general corporate purposes, including repaying maturing debts. The financing capitalizes on favorable interest rates, locking in fixed costs for the next decade.

Bruker Corporation (Nasdaq: BRKR) announced its CE-IVD marked FluoroType^® SARS-CoV-2 varID Q PCR assay, capable of detecting all major variants of SARS-CoV-2, including Omicron (B.1.1.529). The assay identifies key S-gene mutations associated with Omicron and provides viral load results in less than 4 hours. It is validated for use with the FluoroCycler^® XT thermocycler and supports automated extraction via the GenoXtract^® fleXT system. Bruker’s other SARS-CoV-2 assays are also expected to detect the Omicron variant.

Bruker Corporation (Nasdaq: BRKR) announced its acquisition of MOLECUBES NV, enhancing its nuclear molecular imaging (NMI) capabilities. This strategic move aims to expand Bruker's preclinical imaging portfolio with the modular benchtop CUBES™ systems, expected to accelerate NMI adoption in medical and biopharma sectors. MOLECUBES generated approximately Euro 5 million in FY 2020 revenue and will operate within Bruker's BioSpin division, aiming for synergies in research and development.

Bruker Corporation (Nasdaq: BRKR) has announced significant advancements in 4D proteomics workflows, highlighted during the HUPO Reconnect 2021 virtual congress. They introduced a co-marketing agreement with Cellenion for the innovative cellenONE® system, enhancing automation in single-cell proteomics. Additionally, the partnership with Seer enables unprecedented detection of over 3,000 protein groups from human plasma using the Proteograph™ Product Suite. Bruker also expanded its collaboration with PreOmics to showcase the BeatBox™ technology for efficient tissue homogenization, improving proteomic analysis speed and yield.

Bruker Corporation (Nasdaq: BRKR) has announced a quarterly cash dividend of $0.04 per share, scheduled for payment on December 17, 2021, to stockholders of record as of December 1, 2021.

The Board also approved an increase in the annual cash dividend from $0.16 to $0.20 per share, with payments commencing in March 2022, contingent upon quarterly Board approval.

Bruker Corporation (Nasdaq: BRKR) will take part in the 2021 Jefferies London Healthcare Conference on November 16, 2021, at 12:20 PM GMT. Gerald Herman, Executive Vice President & Chief Financial Officer, will lead an analyst-moderated Q&A session. A live audio webcast can be accessed via the company's Investor Relations website at https://ir.bruker.com. A replay will be available for 30 days post-event in the 'Events & Presentations' section.

Bruker Corporation (Nasdaq: BRKR) announced major advancements in its mass spectrometry capabilities at the 69th ASMS meeting in Philadelphia. The new CCS-enabled technologies for the timsTOF Pro 2, timsTOF fleX, and timsTOF SCP systems enhance proteomics workflows with rapid, high-sensitivity analysis. Key features include the identification of over 8,000 cell lysate proteins, a new OligoQuest software for RNA analysis, and the SCiLS autopilot for automated mass spectrometry imaging. These innovations aim to improve proteomics research, particularly in cancer biology and therapeutic development.

Bruker Corporation (Nasdaq: BRKR) reported Q3 2021 revenues of $608.9 million, a 19.1% increase year-over-year, with organic growth of 17.8%. GAAP EPS rose 63% to $0.57, while non-GAAP EPS increased 50% to $0.63. Operating income stood at $113.2 million with margins improving to 18.6%. For the first nine months, revenues totaled $1,734.4 million, an increase of 27.5%. The company raised its FY 2021 guidance, expecting revenue growth of 19.5%-20.5% and non-GAAP EPS between $2.05 and $2.09.

Bruker Corporation (Nasdaq: BRKR) will announce its third quarter 2021 financial results on November 1, 2021, after market close. A conference call is scheduled for 4:30 p.m. ET to discuss the results and current business trends. Investors can access the webcast at ir.bruker.com; a slide presentation will be available prior to the call. Pre-registration is encouraged to expedite entry. A replay will be available from one hour after the call until December 1, 2021.